These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15562330)

  • 1. Proteolytic Enzymes as Therapeutic Targets - Keystone Symposium. Targeting ICE and ACE. 3-8 February 2002, Keystone, CA, USA.
    Loukas A
    IDrugs; 2002 Mar; 5(3):220-1. PubMed ID: 15562330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolytic enzymes as therapeutic targets - Keystone Symposium. 3-8 February 2002, Keystone, CO, USA.
    Creemers J
    IDrugs; 2002 Mar; 5(3):216-9. PubMed ID: 15562329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of novel angiotensin-I-converting enzyme inhibitory peptides from protease-hydrolyzed marine shrimp Acetes chinensis.
    Hai-Lun H; Xiu-Lan C; Cai-Yun S; Yu-Zhong Z; Bai-Cheng Z
    J Pept Sci; 2006 Nov; 12(11):726-33. PubMed ID: 16981241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral proteases and phosphorodiesterase inhibitors.
    Agathangelou P
    IDrugs; 1999 Jun; 2(6):523-5. PubMed ID: 16127607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease proteomics: revealing protease in vivo functions using systems biology approaches.
    Doucet A; Overall CM
    Mol Aspects Med; 2008 Oct; 29(5):339-58. PubMed ID: 18571712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR solution structures of the apo and peptide-inhibited human rhinovirus 3C protease (Serotype 14): structural and dynamic comparison.
    Bjorndahl TC; Andrew LC; Semenchenko V; Wishart DS
    Biochemistry; 2007 Nov; 46(45):12945-58. PubMed ID: 17944485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of active angiotensin-I converting enzyme inhibitory peptides derived from bovine beta-casein by recombinant DNA technologies.
    Losacco M; Gallerani R; Gobbetti M; Minervini F; De Leo F
    Biotechnol J; 2007 Nov; 2(11):1425-34. PubMed ID: 17722167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioinformatics of proteases in the MEROPS database.
    Barrett AJ
    Curr Opin Drug Discov Devel; 2004 May; 7(3):334-41. PubMed ID: 15216937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking the pathogenesis of asthma - Keystone Symposium. 8-13 February 2002, Santa Fe, NM, USA.
    Zuany-Amorim C
    IDrugs; 2002 Mar; 5(3):231-3. PubMed ID: 15562334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting proteases: successes, failures and future prospects.
    Turk B
    Nat Rev Drug Discov; 2006 Sep; 5(9):785-99. PubMed ID: 16955069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where do the immunostimulatory effects of oral proteolytic enzymes ('systemic enzyme therapy') come from? Microbial proteolysis as a possible starting point.
    Biziulevicius GA
    Med Hypotheses; 2006; 67(6):1386-8. PubMed ID: 16870353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
    Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
    J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.
    Blum A; Böttcher J; Sammet B; Luksch T; Heine A; Klebe G; Diederich WE
    Bioorg Med Chem; 2008 Sep; 16(18):8574-86. PubMed ID: 18760609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin I-converting enzyme inhibitor peptides derived from the endostatin-containing NC1 fragment of human collagen XVIII.
    Farias SL; Sabatini RA; Sampaio TC; Hirata IY; Cezari MH; Juliano MA; Sturrock ED; Carmona AK; Juliano L
    Biol Chem; 2006 May; 387(5):611-6. PubMed ID: 16740133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin I-converting enzyme inhibitory peptide derived from glycinin, the 11S globulin of soybean (Glycine max).
    Mallikarjun Gouda KG; Gowda LR; Rao AG; Prakash V
    J Agric Food Chem; 2006 Jun; 54(13):4568-73. PubMed ID: 16786999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent.
    Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S
    Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates.
    Medintz IL; Clapp AR; Brunel FM; Tiefenbrunn T; Uyeda HT; Chang EL; Deschamps JR; Dawson PE; Mattoussi H
    Nat Mater; 2006 Jul; 5(7):581-9. PubMed ID: 16799548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin converting enzyme inhibitors].
    Sramko M; Remko M
    Ceska Slov Farm; 2006 Jul; 55(4):160-7. PubMed ID: 16921734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.